ATR and cancer: Since dysregulation of the DNA damage response (DDR) is common in cancer, and there is precedent for DDR defects to confer sensitivity to DDR inhibitors (HRR defects and PARP inhibitors)), we focussed on DDR defects as potential determinants of sensitivity to single agent ATR inhibition.